Monthly Archives: April 2015

What are the External Models of Pharma R&D?

What are some fundamental problems that pharmaceutical companies are facing and how are they solving them? The authors (Merck, Sanofi, and The Boston Consulting Group) cite decreased Research and Development (R&D) productivity and rising customer expectations as challenges to pharma.

What are the External Models of Pharma R&D?

What are some fundamental problems that pharmaceutical companies are facing and how are they solving them? The authors (Merck, Sanofi, and The Boston Consulting Group) cite decreased Research and Development (R&D) productivity and rising customer expectations as challenges to pharma.

Why did Merck Develop a Screening Paradigm for Combination Therapies?

Sometimes two drugs are better than one. Combinations of therapies can be more effective than just one in isolation, thus a lower doses of each can be administered. The authors cite and test in this paper antiinfectives and cancer chemotherapeutics

Why did Merck Develop a Screening Paradigm for Combination Therapies?

Sometimes two drugs are better than one. Combinations of therapies can be more effective than just one in isolation, thus a lower doses of each can be administered. The authors cite and test in this paper antiinfectives and cancer chemotherapeutics

How can Drugs be Made Available to the Developing World?

John Kay of the London School of Economics wrote a piece in the Financial Times (UK) in March 2015 entitled “The True Value of a Life is Not About the Pharmaceutical costs” advocating for a national license tax to make

How can Drugs be Made Available to the Developing World?

John Kay of the London School of Economics wrote a piece in the Financial Times (UK) in March 2015 entitled “The True Value of a Life is Not About the Pharmaceutical costs” advocating for a national license tax to make

Is There a Decline in Financial Returns From New Drugs?

Industry observers predicted that the profitability of the pharmaceutical industry would decline as a result of the expiration of patents of blockbuster drug. Blockbuster drugs generate $1 billion in revenue a year and include Lipitor (Pfizer) at $12.5 billion/year, Plavix

Is There a Decline in Financial Returns From New Drugs?

Industry observers predicted that the profitability of the pharmaceutical industry would decline as a result of the expiration of patents of blockbuster drug. Blockbuster drugs generate $1 billion in revenue a year and include Lipitor (Pfizer) at $12.5 billion/year, Plavix